SKion GmbH
https://www.skion.de/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SKion GmbH
Roche Could Have The Best Obesity Pill
That is, if very early data in a handful of patients are borne out in later, larger studies.
Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry
Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?
Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data
Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue
EASL: Tirzepatide Is The One To Beat In MASH
An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.
Company Information
- Industry
- Miscellaneous
- Other Names / Subsidiaries
-
- Altana AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice